On March 21, 2022 MaaT Pharma (EURONEXT: MAAT – the "Company"), a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer, reported the implementation of a liquidity agreement with Kepler Cheuvreux to enhance the liquidity of the Maat Pharma shares admitted to trading on Euronext Paris (Press release, MaaT Pharma, MAR 21, 2022, View Source [SID1234610466]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The implementation of this liquidity agreement, pursuant to the authorization granted by the resolution of the General Meeting, will be carried out in accordance with the legal framework in force, and more particularly to the provisions of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of April 16, 2014 on market abuse (MAR), Commission Delegated Regulation (EU) 2016/908 of February 26, 2016 supplementing Regulation (EU) No. 596/2014 of the European Parliament and of the Council with regulatory technical standards on the criteria, procedure and requirements for the establishment of an admitted market practice and the requirements for maintaining, discontinuing or modifying its conditions of admission, Articles L. 225-209 et seq. of the French Commercial Code and AMF decision no. 2021-01 of June 22, 2021, applicable as of July 1, 2021.
The following resources will be allocated to the liquidity account:
200,000 euros
The execution of the liquidity contract could be suspended under the conditions set out in Article 5 of AMF Decision 2021-01 of 22 June 2021.
The liquidity contract will be implemented as of March 22, 2022, and may be terminated:
at any time by MaaT Pharma without notice
at any time by Kepler Cheuvreux, subject to thirty (30) calendar days’ notice
without notice and without formality if the shares are transferred to another stock market